Home|Journals|Articles by Year|Audio Abstracts

Original Research

RMJ. 2021; 46(4): 761-764

Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease

Kashif Rasheed Shaikh, Shumaila Shaikh, Muhammad Atif Ata, Azhar Memon, Umair Ali Soomro, Shumail Saeed Siddiqui.


Objective: To determine the therapeutic efficacy of silymarin on liver aminotransferases in non-alcoholic fatty liver disease (NAFLD).
Methodology: This case control study was carried out at Suleman Roshan Medical College from August 2019 to March 2020. A sample of 200 diagnosed cases of NAFLD was divided into 2 groups; cases received 2 tablets silymarin (200 mg) per day for 12 weeks and controls received placebo. Baseline and after 12 weeks blood samples were taken for the liver aminotransferase measurements. Data were analyzed on SPSS version 21.0.
Results: Frequency of fatty liver disease at baseline in cases and controls was noted as: grade 1- 32% vs. 31%, grade 2 - 60% vs. 61% and grade 3- 8% vs. 7% (p=0.91. ALT in cases decreased from 89.7±7.31 to 67.3±3.9 IU/mL and AST decreased from 72.3±5.9 to 53.9±5.7 IU/mL while ALT in controls decreased from 88.9±8.1 to 79.3±7.1 and AST from 71.3±5.3 to 70.9±6.13 (p=0.0001).
Conclusion: Silymarin therapy effectively improved NAFLD with improvement of liver aminotransferases.

Key words: Silylmarin, NAFLD, sonography, ALT, AST.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.